910 related articles for article (PubMed ID: 19808268)
1. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
Anand IS; Rector TS; Kuskowski M; Thomas S; Holwerda NJ; Cohn JN
Circ Heart Fail; 2008 May; 1(1):34-42. PubMed ID: 19808268
[TBL] [Abstract][Full Text] [Related]
2. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
3. C-reactive protein in heart failure: prognostic value and the effect of valsartan.
Anand IS; Latini R; Florea VG; Kuskowski MA; Rector T; Masson S; Signorini S; Mocarelli P; Hester A; Glazer R; Cohn JN;
Circulation; 2005 Sep; 112(10):1428-34. PubMed ID: 16129801
[TBL] [Abstract][Full Text] [Related]
4. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
[TBL] [Abstract][Full Text] [Related]
5. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
Baruch L; Glazer RD; Aknay N; Vanhaecke J; Heywood JT; Anand I; Krum H; Hester A; Cohn JN
Am Heart J; 2004 Dec; 148(6):951-7. PubMed ID: 15632877
[TBL] [Abstract][Full Text] [Related]
6. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT.
Anand IS; Kuskowski MA; Rector TS; Florea VG; Glazer RD; Hester A; Chiang YT; Aknay N; Maggioni AP; Opasich C; Latini R; Cohn JN
Circulation; 2005 Aug; 112(8):1121-7. PubMed ID: 16103233
[TBL] [Abstract][Full Text] [Related]
7. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
Zanchetti A; Julius S; Kjeldsen S; McInnes GT; Hua T; Weber M; Laragh JH; Plat F; Battegay E; Calvo-Vargas C; Cieśliński A; Degaute JP; Holwerda NJ; Kobalava J; Pedersen OL; Rudyatmoko FP; Siamopoulos KC; Störset O
J Hypertens; 2006 Nov; 24(11):2163-8. PubMed ID: 17053536
[TBL] [Abstract][Full Text] [Related]
8. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
Anand IS; Rector TS; Kuskowski M; Adourian A; Muntendam P; Cohn JN
Eur J Heart Fail; 2013 May; 15(5):511-8. PubMed ID: 23291728
[TBL] [Abstract][Full Text] [Related]
9. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT).
Butler J; Anand IS; Kuskowski MA; Rector T; Carson P; Cohn JN;
Congest Heart Fail; 2010; 16(5):191-5. PubMed ID: 20887614
[TBL] [Abstract][Full Text] [Related]
10. Effect of Valsartan on hospitalization: results from Val-HeFT.
Carson P; Tognoni G; Cohn JN
J Card Fail; 2003 Jun; 9(3):164-71. PubMed ID: 12815565
[TBL] [Abstract][Full Text] [Related]
11. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT.
Krum H; Latini R; Maggioni AP; Anand I; Masson S; Carretta E; Ingrillì F; Pettinati G; Glazer R; Tognoni G; Cohn J
Int J Cardiol; 2007 Jun; 119(1):48-53. PubMed ID: 17049646
[TBL] [Abstract][Full Text] [Related]
12. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.
Anand IS; Kempf T; Rector TS; Tapken H; Allhoff T; Jantzen F; Kuskowski M; Cohn JN; Drexler H; Wollert KC
Circulation; 2010 Oct; 122(14):1387-95. PubMed ID: 20855664
[TBL] [Abstract][Full Text] [Related]
13. Association of blood pressure and its evolving changes with the survival of patients with heart failure.
Grigorian-Shamagian L; Gonzalez-JuAnatey JR; Vazquez R; Cinca J; Bayes-Genis A; Pascual D; Fernandez-Palomeque C; Bardaji A; Almendral J; Nieto V; Macaya C; Jimenez RP; de Luna AB;
J Card Fail; 2008 Sep; 14(7):561-8. PubMed ID: 18722321
[TBL] [Abstract][Full Text] [Related]
14. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients.
Nakamura T; Fujii S; Hoshino J; Saito Y; Mizuno H; Saito Y; Kurabayashi M
Hypertens Res; 2005 Dec; 28(12):937-43. PubMed ID: 16671331
[TBL] [Abstract][Full Text] [Related]
15. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
[TBL] [Abstract][Full Text] [Related]
16. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
[TBL] [Abstract][Full Text] [Related]
17. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
Cohn JN; Anand IS; Latini R; Masson S; Chiang YT; Glazer R;
Circulation; 2003 Sep; 108(11):1306-9. PubMed ID: 12939207
[TBL] [Abstract][Full Text] [Related]
18. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of valsartan for treatment of hypertension: patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study).
Van der Niepen P; Woestenburg A; Brié H; Vancayzeele S; MacDonald K; Denhaerynck K; Lee C; Hermans C; Abraham I
Ann Pharmacother; 2009 May; 43(5):849-61. PubMed ID: 19351876
[TBL] [Abstract][Full Text] [Related]
20. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Aguilar D; Solomon SD; Køber L; Rouleau JL; Skali H; McMurray JJ; Francis GS; Henis M; O'Connor CM; Diaz R; Belenkov YN; Varshavsky S; Leimberger JD; Velazquez EJ; Califf RM; Pfeffer MA
Circulation; 2004 Sep; 110(12):1572-8. PubMed ID: 15364810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
